Browsing Tag

Adagene Inc.

Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody®…

Eli Pacheco Dec 17, 2022 0

SAN DIEGO and SUZHOU, China, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies,…

Health

Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety,…

Eli Pacheco Sep 10, 2022 0

- Best-in-class profile demonstrated with repeat dosing across dose levels - - Antitumor activity observed in cold tumors with steady accumulation of activated ADG126 - - On track in…

Health

Adagene Presents Data Demonstrating First and Best-in-Class Potential for…

Eli Pacheco Apr 9, 2022 0

- Poster presentations showcase SAFEbody® precision masking technology applicability across targets and modalities – - IND or equivalent filings planned for two new product candidates…